Guide on Developing Clostridioides Difficile Infection

FDA has issued updated guidance for companies developing therapies to treat, prevent or reduce recurrence of Clostridioides difficile infection (CDI), outlining clinical trial expectations as the agency seeks to encourage new options for a disease that continues to cause serious illness and frequent relapse. The guidance covers development programs for drugs intended to treat active CDI, prevent infection in high-risk patients, or reduce the risk of recurrence after successful treatment of an initial episode. FDA says the document applies to both small-molecule drugs and therapeutic biologics regulated by the CDER, though it excludes products such as fecal microbiota transplantation therapies, probiotics, vaccines and live biotherapeutic products.

FDA describes CDI as a toxin-mediated disease caused by Clostridioides difficile, an anaerobic spore-forming bacterium that produces toxins responsible for intestinal inflammation and severe diarrhea. Certain strains, including the hypervirulent 027/BI/NAP1 lineage, also produce a binary toxin associated with more severe disease.

Under the guidance, FDA recommends that pivotal trials for CDI therapies generally be randomized, double-blind and controlled. Active comparators are recommended for treatment studies, while placebo-controlled designs may be acceptable in prevention or recurrence-reduction trials.

For investigational therapies intended to treat active infection, FDA says sponsors may pursue either superiority or noninferiority study designs compared with standard-of-care treatment. However, the agency said superiority designs are preferred for drugs intended to reduce recurrence or prevent CDI altogether unless sponsors can adequately justify a noninferiority margin.

FDA also outlines recommended clinical trial time points, including an end-of-treatment assessment, a test-of-cure visit two days after therapy completion and a late follow-up evaluation at least four weeks after treatment ends.

The guidance emphasizes that efficacy assessments should focus on clinically meaningful outcomes rather than microbiological testing alone. For treatment trials, FDA recommends a primary endpoint based on survival and resolution of diarrhea without the need for additional CDI therapy through the test-of-cure visit. The agency also identified sustained clinical response — defined as remaining alive and recurrence-free for at least four weeks after treatment — as an important secondary endpoint.

For prevention trials, FDA says the primary endpoint should measure whether participants develop CDI during a predefined follow-up period.

The agency advises sponsors to discuss overall development strategies with FDA early in clinical development and said, in some cases, a single adequate and well-controlled study supported by confirmatory evidence may be sufficient to establish effectiveness.